I e-mailed Colker again and he is still pretty adamant about not using Aromasin...he calls it "the black sheep of AIs" According to him:
"In clinical practice we tend to only use Aromasin in post-menopausal women that have estrogen receptor positive breast cancer with metasteses that has been unresponsive to Tamoxifan therapy. We use it to augment because, even though it is an irreversible aromatase inhibitor, it tends to be a lousy stand-alone therapy for these types of women."
All in all he has still not directly clarified that much for me on this topic, pretty much all he says is that it's a bad idea. Anyway, I might ask him about it some more because it seems I'm not getting very clear comments...maybe my wording of my questions is off, but everything I've asked him about it comes from the Anthony Roberts report and what some of you here who are inclined to advocate this strategy.